OOIR: Observatory of International Research

Papers

(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	98
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	77
Early initiation of SGLT2 inhibitors after acute myocardial infarction	69
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	64
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	60
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	48
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	46
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead	42
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus	41
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	37
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study	37
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study	37
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	34
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	34
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	34
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	30
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	29
All about clinical trials	27
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	26
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	26
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	25
New ways of mitigating aldosterone in cardiorenal disease	25

Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	25
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data	25